Inhibikase Therapeutics (IKT) director exercises 21,854 stock options at $1.26
Rhea-AI Filing Summary
Inhibikase Therapeutics director Dennis N. Berman exercised stock options covering 21,854 shares of common stock on July 30, 2026 at an exercise price of $1.26 per share. The fully vested options were converted, leaving 0 options from this grant and 21,854 common shares held directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 21,854 shares
Net Buy
2 txns
Insider
BERMAN DENNIS N
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F1 | 21,854 | $0.00 | $0.00 |
| Exercise | Common Stock | 21,854 | $1.26 | $28K |
Holdings After Transaction:
Stock Option (Right to Buy) — 0 shares (Direct);
Common Stock — 21,854 shares (Direct)
Footnotes (1)
- F1. The options are fully vested and exercisable.
Key Figures
Options Exercised: 21,854 shares
Exercise Price: $1.26 per share
Common Shares Acquired: 21,854 shares
+2 more
5 metrics
Options Exercised
21,854 shares
Stock options exercised and converted into common stock on July 30, 2026
Exercise Price
$1.26 per share
Exercise or conversion price of the stock options
Common Shares Acquired
21,854 shares
Common stock received upon option exercise on July 30, 2026
Common Shares Held After
21,854 shares
Directly owned common stock position following the reported transaction
Option Expiration Date
2026-08-31
Original expiration date of the exercised stock options
Key Terms
Stock Option (Right to Buy), Common Stock, Exercise or conversion of derivative security, fully vested and exercisable
4 terms
Stock Option (Right to Buy) financial
"Security title reported as Stock Option (Right to Buy)"
Common Stock financial
"Underlying security title identified as Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Exercise or conversion of derivative security financial
"Transaction code description is Exercise or conversion of derivative security"
fully vested and exercisable financial
"Footnote states the options are fully vested and exercisable"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Inhibikase Therapeutics (IKT) report for Dennis N. Berman?
Dennis N. Berman exercised stock options covering 21,854 shares of Inhibikase Therapeutics common stock on July 30, 2026 at an exercise price of $1.26 per share, converting those options into directly owned shares and eliminating this specific option position entirely.
What was the exercise price of the options Dennis N. Berman exercised in Inhibikase Therapeutics (IKT)?
The options exercised by Dennis N. Berman had an exercise price of $1.26 per share. Upon exercise on July 30, 2026, they were converted into 21,854 shares of common stock at this price, according to the reported transaction details.
Were Dennis N. Berman’s Inhibikase Therapeutics (IKT) options vested at the time of exercise?
Yes, the options exercised by Dennis N. Berman were fully vested and exercisable at the time of the transaction. A related footnote specifies this status, indicating no remaining vesting conditions on the options that were converted into common shares.
What happened to the specific stock option grant for Dennis N. Berman at Inhibikase Therapeutics (IKT)?
The specific stock option grant for 21,854 underlying shares was fully exercised and now shows 0 options remaining. Those options, previously fully vested and exercisable, were converted into an equivalent number of directly held common shares on July 30, 2026.